

1*H*-Pyrido[3,4-*b*]azepine-2,5(3*H*,4*H*)-dione: a hydrogen-bonded dimeric structure

Xiao-Dan Gu,^a Fu-Hui Zhou,^a
Sheng-Wen Wang,^a Jian-Cheng
Deng^{a*} and Jing-Wei Xu^{b‡}

^aThe College of Chemistry, Xiangtan University, Hunan, 411105, People's Republic of China, and ^bNational Analytical Research Center of Electrochemistry and Spectroscopy, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, People's Republic of China

‡ Additional correspondence author, e-mail jwxu@ciac.jl.cn

Correspondence e-mail: djcwye@163.com

Key indicators

Single-crystal X-ray study

$T = 293$ K

Mean $\sigma(\text{C}-\text{C}) = 0.003$ Å

R factor = 0.050

wR factor = 0.124


Data-to-parameter ratio = 13.4

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

In the asymmetric unit of the title compound, $\text{C}_9\text{H}_8\text{N}_2\text{O}_2$, there are two crystallographically independent molecules, each of which forms a dimer, *via* $\text{N}-\text{H} \cdots \text{O}$ hydrogen bonds, with an inversion-related molecule.

Comment

The title compound, (I), is an isomer of 6,7,8,9-tetrahydro-5*H*-pyrid[2,3-*b*]azepine-5,8-dione (Gu *et al.*, 2006). It is an intermediate in the synthesis of 1-azakepallone (Kunick *et al.*, 2004), which is an inhibitor of glycogen synthase kinase-3 (Doble & Woodgett, 2003) and a potential antidiabetic drug (Wagmann & Nuss, 2001).



In the crystal structure of (I), the seven-membered rings in the two crystallographically independent molecules have a half-chair-like conformation. Each independent molecule forms a dimer, *via* $\text{N}-\text{H} \cdots \text{O}$ hydrogen bonds, with a molecule related by an inversion center (Fig. 1 and Table 1). These hydrogen bonds generate $R_2^2(8)$ rings (Bernstein *et al.*, 1995). The dimers are connected by weak $\text{C}-\text{H} \cdots \text{N}$ and $\text{C}-\text{H} \cdots \text{O}$ hydrogen bonds (Fig. 2 and Table 1).

Experimental

The title compound was prepared from 3-aminopyridine (purchased from Shanhai Minghe Chemical Co.) according to a literature method (Estel *et al.*, 1989; Bhaskar & Rajesh, 1996; Kunick *et al.*, 2003). Single crystals suitable for X-ray diffraction were obtained from an ethanol solution.

Crystal data

$\text{C}_9\text{H}_8\text{N}_2\text{O}_2$
 $M_r = 176.17$
Monoclinic, $P2_1/n$
 $a = 11.346$ (3) Å
 $b = 10.708$ (2) Å
 $c = 13.161$ (3) Å
 $\beta = 93.219$ (4)°
 $V = 1596.5$ (6) Å³

$Z = 8$
 $D_x = 1.466$ Mg m⁻³
Mo $K\alpha$ radiation
 $\mu = 0.11$ mm⁻¹
 $T = 293$ (2) K
Needle, colorless
 $0.36 \times 0.16 \times 0.11$ mm

Data collection

Bruker SMART CCD area-detector diffractometer
 φ and ω scans
 Absorption correction: multi-scan (SADABS; Sheldrick, 1996)
 $T_{\min} = 0.962$, $T_{\max} = 0.988$

8803 measured reflections
 3139 independent reflections
 2116 reflections with $I > 2\sigma(I)$
 $R_{\text{int}} = 0.034$
 $\theta_{\text{max}} = 26.1^\circ$

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.050$
 $wR(F^2) = 0.124$
 $S = 1.01$
 3139 reflections
 235 parameters
 H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.0573P)^2 + 0.0991P]$
 where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{\text{max}} < 0.001$
 $\Delta\rho_{\text{max}} = 0.21 \text{ e } \text{Å}^{-3}$
 $\Delta\rho_{\text{min}} = -0.16 \text{ e } \text{Å}^{-3}$

Table 1

Hydrogen-bond geometry (Å, °).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
$N2-H2A\cdots O2^i$	0.86	2.04	2.885 (2)	166
$N4-H4\cdots O4^{ii}$	0.86	2.10	2.893 (2)	153
$C7-H7A\cdots N1^{iii}$	0.97	2.61	3.499 (3)	152
$C15-H15B\cdots O1^{iv}$	0.97	2.50	3.419 (3)	158

Symmetry codes: (i) $-x + 1, -y, -z + 1$; (ii) $-x, -y, -z + 1$; (iii) $-x + \frac{3}{2}, y + \frac{1}{2}, -z + \frac{3}{2}$; (iv) $x - 1, y, z$.

H atoms were positioned geometrically ($C-H = 0.93-0.97$ and $N-H = 0.86 \text{ Å}$) and refined as riding with $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C,N})$.

Data collection: SMART (Bruker, 1998); cell refinement: SAINT (Bruker, 2003); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics: SHELXTL (Bruker, 1997); software used to prepare material for publication: SHELXTL.

This work is supported by Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, People's Republic of China.

References

Bernstein, J., Davis, R. E., Shimon, L. & Chang, N.-L. (1995). *Angew. Chem. Int. Ed. Engl.* **34**, 1555–1573.
 Bhaskar, D.-H. & Rajesh, H.-D. (1996). *Tetrahedron Lett.* **37**, 6375–6378.
 Bruker (1997). SHELXTL. Version 5.10. Bruker AXS, Inc., Madison, Wisconsin, USA.
 Bruker (1998). SMART. Version 5.0. Bruker AXS, Inc., Madison, Wisconsin, USA.
 Bruker (2003). SAINT. Version 6. Bruker AXS, Inc., Madison, Wisconsin, USA.
 Doble, B. W. & Woodgett, J. R. (2003). *J. Cell Sci.* **116**, 1175–1186.
 Estel, L., Marsais, F., Godard, A. & Quéguiner, G. (1989). *J. Heterocycl. Chem.* **26**, 105–112.
 Gu, X.-D., Zhou, F.-H., Zhou, H., Xu, J.-W. & Deng, J.-C. (2006). *Acta Cryst. E62*, o2918–o2919.




Figure 1 The structures of the two independent hydrogen-bonded dimers of (I), with the atom-labeling scheme and 30% probability displacement ellipsoids. Hydrogen bonds are shown as dashed lines.




Figure 2 A view of the packing of (I) along the c axis. Hydrogen bonds are shown as dashed lines.

Kunick, C., Lauenroth, K., Leost, M., Meijer, L. & Lemcke, T. (2004). *Bioorg. Med. Chem. Lett.* **14**, 413–416.
 Kunick, C., Lauenroth, K., Wiekling, K., Xie, X., Schultz, C., Gussio, R., Zaharevitz, D., Leost, M., Meijer, L., Weber, A., Jørgensen, F. S. & Lemcke, T. (2003). *J. Med. Chem.* **47**, 22–36.
 Sheldrick, G. M. (1996). SADABS. University of Göttingen, Germany.
 Sheldrick, G. M. (1997). SHELXS97 and SHELXL97. University of Göttingen, Germany.
 Wagnmann, A. S. & Nuss, J. M. (2001). *Curr. Pharm. Des.* **7**, 417–450.